June 10, 2022 Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Read More
June 6, 2022 Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors
Read More
May 19, 2022 Ryvu Therapeutics to Participate in Upcoming Investor Conferences
Read More
May 18, 2022 Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read More
May 12, 2022 Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703).
Read More
April 27, 2022 Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Read More
April 11, 2022 Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting
Read More
March 15, 2022 Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Read More
March 8, 2022 Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting
Read More
January 17, 2022 Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer
Read More
Posts navigation
